- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Patent holdings for IPC class C07D 405/06
Total number of patents in this class: 2416
10-year publication summary
|
180
|
175
|
230
|
176
|
138
|
126
|
139
|
128
|
139
|
103
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 21334 |
42 |
| Takeda Pharmaceutical Company Limited | 2708 |
42 |
| VALO Health, Inc. | 193 |
34 |
| Merck Sharp & Dohme LLC | 3734 |
30 |
| Janssen Pharmaceutica N.V. | 3129 |
29 |
| Eisai R&D Management Co., Ltd. | 1161 |
29 |
| Bristol-myers Squibb Company | 4751 |
24 |
| F. Hoffmann-La Roche AG | 7784 |
23 |
| Pulmocide Limited | 40 |
23 |
| Shionogi & Co., Ltd. | 893 |
20 |
| Orion Corporation | 798 |
18 |
| Boehringer Ingelheim International GmbH | 4485 |
17 |
| Allergan, Inc. | 2144 |
17 |
| Temple University of the Commonwealth System of Higher Education | 642 |
16 |
| Centre National de La Recherche Scientifique | 11143 |
14 |
| Glaxosmithkline Intellectual Property Development Limited | 783 |
14 |
| Alkermes Pharma Ireland Limited | 254 |
14 |
| Hoffmann-La Roche Inc. | 3876 |
13 |
| AstraZeneca AB | 2835 |
13 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3031 |
13 |
| Other owners | 1971 |